ArticleInsights into imaging2025
Mediation and prognostic value of apparent diffusion coefficient in HCC patients receiving immune checkpoint inhibitors.
Article in Insights into imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectivesThe study investigated the potential association between tumor size and inflammation from the standpoint of apparent diffusion coefficient (ADC) and the prognostic significance of ADC in hepatocellular carcinoma (HCC) patients treated with immune checkpoint inhibitors (ICIs). MATERIALS AND
methodsThis retrospective study ultimately included 255 HCC patients receiving ICIs, among whom 168 underwent posttreatment diffusion-weighted imaging at three months. The study analyzed the correlations among pretreatment tumor maximum diameter, inflammatory markers (neutrophil to lymphocyte ratio, NLR; platelet to lymphocyte ratio, PLR), and ADC (substantial tumor ADC, sADC; whole tumor ADC, wADC), as well as exploring the association between tumor maximum diameter and inflammatory markers regarding ADC. This study further focused on the prognostic value of baseline and relative change in ADC in HCC patients receiving ICIs.
resultsThe study found a potential relationship between tumor maximum diameter and inflammatory markers regarding sADC. Multivariate Cox regression showed that higher sADC was associated with longer overall survival (OS) (HR: 0.63, 95% CI: 0.43-0.91, p = 0.015). Additionally, the relative change in sADC (ΔsADC) positive group exhibited better progression-free survival (12 vs 6.4 months, p < 0.001) and OS (20.5 vs 13.3 months, p < 0.001) compared to the ΔsADC non-positive group, serving as an independent prognostic factor for HCC patients receiving ICIs.
conclusionsThe association between tumor burden and inflammatory markers was observed regarding sADC, with baseline sADC and relative change promising as prognostic imaging biomarkers in HCC patients receiving ICIs. CRITICAL RELEVANCE STATEMENT: The substantial tumor ADC is an important imaging feature revealing the potential association between tumor burden and inflammation, and its prognostic role for patients with HCC receiving ICIs. KEY POINTS: The sADC could indirectly reflect tumor microenvironment characteristics. The association between tumor burden and inflammatory markers was observed regarding sADC. Baseline sADC and its change predict prognosis in ICI-treated HCC patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.